Finance Watch: Volatility Impacts IPOs In The US, But Biopharma Is A Standout
Public Company Edition: Grifols announced its intention to sell shares for a portion of its US business through an initial public offering, although a first quarter report noted that the IPO window did not widen as much as expected in Q1; the follow-on market, however, was robust in late March.
Scrip - March 27, 2026

Rocket Has Liftoff With Kresladi Approval, But Market Remains Small
The FDA approved the gene therapy for certain patients with leukocyte adhesion deficiency, a population the company expects to number in the single digits.
Scrip - March 27, 2026

Otsuka Returns To Post-Traumatic Stress Disorder With Transcend Buyout
Driven by its interest in Phase III PTSD drug TSND-201, Otsuka will pay $700m up front to acquire privately held Transcend. The deal follows termination of Otsuka’s efforts with Rexulti in PTSD.
Scrip - March 27, 2026

FDA Finalizes Guidance On Including Patient Preference Information In Device Submissions
The US FDA has published final guidance on patient preference information to enhance its evaluation of medical devices. The agency says the guidance strengthens patient engagement in the development of devices patients use to manage their health and well-being.
Medtech Insight - March 27, 2026

Cancer Biomarker Test Advertising Largely OK, NAD Says
Viome Life Sciences needs to update advertising for its CancerDetect Oral & Throat at-home test to clarify that the test detects cancer biomarkers but cannot diagnose cancer, the Advertising Division said after a recent review. However, the NAD allowed most of the company's advertising to stand.
Medtech Insight - March 27, 2026

US FDA Seeks Higher Quality Responses To Form 483 Inspection Findings
The US FDA aims to prevent poor quality or incomplete responses to Form 483 inspection observations with a new draft guidance that describes the structure and content for concise, factual and effective corrective action responses.
Generics Bulletin - March 27, 2026

Chances Slimmer For Wave’s WVE-007 After Lower BMI Patients Fail To Shift Weight
Disappointing results after six months from the small-interfering RNA candidate in obesity.
Scrip - March 27, 2026

Sweden Encouraging Switch With Legislation For New OTC Category
Sweden looks set to join the small group of countries with a pharmacist-only category to help make more drugs available without a prescription.
HBW Insight - March 27, 2026

Henlius-Organon Denosumab Biosimilars To Enter Canada In 2026
Henlius and its commercial partner Organon have ticked off another market for their denosumab biosimilar pair.
Generics Bulletin - March 27, 2026

Pharma’s Pipeline Size Dipped In 2025
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
Scrip - March 27, 2026

Algorithm Outperforms Human Glucose Monitoring In T2D Study
Patients using an algorithm that analyzes data from a continuous glucose monitor to generate insulin dosing recommendations managed their glucose better than patients who self-monitored, a new study has found.
Medtech Insight - March 27, 2026

CVC Woos Recordati With Buyout Offer In U-Turn
The equity firm was looking to sell its holding in the Italian drugmaker not long ago. Now it is offering €10.90bn for a full takeover.
Scrip - March 27, 2026

HeartBeam Teams Up With Mount Sinai To Bring Clinical-Grade Cardiac Monitoring Into The Home
Medical technology firm HeartBeam and leading heart hospital Mount Sinai want to expand cardiac monitoring capabilities. To achieve this, they are collaborating to advance next-generation AI-ECG technology beyond clinical settings. The joint effort illustrates the growing significance of remote pati
Medtech Insight - March 27, 2026

‘It’s Not A Question Of If, It’s A Question Of When’ – Sandoz’s Haruvi On US Biosimilar #1 Ambitions
Keren Haruvi, head of Sandoz in North America, discusses the firm’s ambitions to become the number one biosimilars supplier in the US – and at the same time, explains why the US generics market is “not attractive enough to heavily invest to grow.”
Generics Bulletin - March 27, 2026

Japan Nod Adds To Growing Momentum For Richter Biosimilars
Japan’s approval of Mochida and Gedeon Richter’s tocilizumab biosimilar marks a key step in both firms’ commercialization push, adding to an established domestic partnership with Ayumi and reinforcing Richter’s transition from development to market entry.
Generics Bulletin - March 27, 2026

Aurobindo Leverages Stada To Unlock European Market Access
Aurobindo’s CuraTeQ has partnered with Stada to commercialize two approved biosimilars in Europe, marking a shift toward execution as the company builds market access, prioritizes its pipeline and prepares for longer-term growth amid rising competition.
Generics Bulletin - March 27, 2026

AstraZeneca Scores First IL-33 Win In COPD With Tozorakimab
The company has succeeded where rivals have failed by showing impact of the new mechanism in chronic obstructive pulmonary disease in twin Phase III trials, OBERON and TITANIA.
Scrip - March 27, 2026

Novartis Buys Excellergy To Add Early Anti?IgE Allergy Drug
With a deal potentially valued at up to $2bn for Excellergy, Novartis will get access to a next-generation anti-IgE asset currently in Phase I testing.
Scrip - March 27, 2026

China Biotech Sees Deal Potential Beyond Preclinical Assets
Through partnerships overseas, China’s pharma companies are looking to build in-house capabilities in the long run, while domestic biotechs are adjusting their own strategies to drive growth.
Scrip - March 27, 2026

J-Pharma Eyes Progress For Global-First LAT1 Inhibitor After Tokyo IPO
J-Pharma raises funds in Tokyo IPO to progress class-leading LAT1 inhibitor candidate in Phase III for biliary tract cancer.
Scrip - March 27, 2026

Biokin’s Iza-Bren Shows Strengths In IO Combos, First In SCLC
Biokin reports at ELCC strong survival results from a Phase II trial of iza-bren combined with an anti-PD-1 antibody for the first-line treatment of extensive-stage small cell lung cancer, paving the way for more studies of combo regimens comprising the ADC and immuno-oncology agents.
Scrip - March 27, 2026

With Third Personalization Investment In A Year, Herbalife Targets Delivering On ‘Global Scale’
Herbalife says combining Bioniq’s offering with its global manufacturing will enable it to expand personalized nutrition at scale and speed. Deal for stake in Bioniq includes initial $10m at closing and another $45m paid over five years as well as up to $95m based on future performance.
HBW Insight - March 27, 2026